Danaher Co. (NYSE:DHR) Shares Sold by CHICAGO TRUST Co NA

CHICAGO TRUST Co NA decreased its stake in shares of Danaher Co. (NYSE:DHR) by 2.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 12,501 shares of the conglomerate’s stock after selling 296 shares during the period. CHICAGO TRUST Co NA’s holdings in Danaher were worth $3,476,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in DHR. Montis Financial LLC acquired a new stake in shares of Danaher in the third quarter valued at $331,000. Brown Miller Wealth Management LLC lifted its holdings in Danaher by 1.8% in the 3rd quarter. Brown Miller Wealth Management LLC now owns 3,470 shares of the conglomerate’s stock valued at $964,000 after acquiring an additional 60 shares during the last quarter. HCR Wealth Advisors boosted its position in shares of Danaher by 13.4% during the 3rd quarter. HCR Wealth Advisors now owns 933 shares of the conglomerate’s stock valued at $259,000 after purchasing an additional 110 shares in the last quarter. Ritholtz Wealth Management raised its holdings in shares of Danaher by 13.3% in the 3rd quarter. Ritholtz Wealth Management now owns 7,282 shares of the conglomerate’s stock worth $2,025,000 after purchasing an additional 857 shares in the last quarter. Finally, Perfromance Wealth Partners LLC acquired a new stake in Danaher during the third quarter valued at approximately $218,000. 79.05% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Danaher news, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the sale, the senior vice president now directly owns 4,212 shares in the company, valued at $1,130,374.44. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other Danaher news, Director Linda Filler sold 3,928 shares of Danaher stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $279.50, for a total transaction of $1,097,876.00. Following the sale, the director now owns 41,149 shares in the company, valued at $11,501,145.50. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Georgeann Couchara sold 952 shares of the stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the transaction, the senior vice president now owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 39,659 shares of company stock valued at $11,042,433. 11.10% of the stock is owned by company insiders.

Danaher Stock Performance

NYSE:DHR opened at $270.33 on Friday. The firm has a market capitalization of $200.23 billion, a PE ratio of 45.82, a PEG ratio of 4.49 and a beta of 0.83. Danaher Co. has a 1 year low of $182.09 and a 1 year high of $281.70. The company has a current ratio of 1.43, a quick ratio of 1.04 and a debt-to-equity ratio of 0.33. The firm’s fifty day simple moving average is $270.31 and its 200 day simple moving average is $259.20.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, topping analysts’ consensus estimates of $1.57 by $0.15. The business had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The firm’s revenue for the quarter was down 2.9% on a year-over-year basis. During the same period in the previous year, the company posted $2.05 earnings per share. On average, sell-side analysts anticipate that Danaher Co. will post 7.59 EPS for the current year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Friday, September 27th will be paid a $0.27 dividend. The ex-dividend date of this dividend is Friday, September 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.40%. Danaher’s payout ratio is 18.31%.

Analysts Set New Price Targets

Several research analysts have issued reports on the company. TD Cowen upped their price target on Danaher from $290.00 to $310.00 and gave the company a “buy” rating in a report on Wednesday, July 24th. Bank of America boosted their price objective on Danaher from $270.00 to $275.00 and gave the stock a “neutral” rating in a report on Wednesday, July 24th. Evercore ISI raised their price objective on shares of Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Robert W. Baird boosted their target price on shares of Danaher from $271.00 to $278.00 and gave the company an “outperform” rating in a research note on Wednesday, July 24th. Finally, Leerink Partners increased their price target on shares of Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 24th. Seven analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $282.12.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.